See Saghmos Therapeutics’ activity on LinkedIn

7mo Edited

We are excited to announce a Notice of Allowance from the Japanese Patent Office for a patent for our Phase 3-ready product, ST-62516 (trimetazidine), a cardiorenal metabolic modulator. The patent will provide exclusivity through 2037, with broad claims for the reduction of acute kidney injury in patients with chronic kidney disease (CKD) undergoing procedures with contrast dyes. https://lnkd.in/egWKrZBK

Saghmos Therapeutics Announces Receipt of Notice of Allowance from Japanese Patent Office for Phase 3-Ready Cardiorenal Metabolic Modulator ST-62516

businesswire.com

7 Comments

Sara Jane Demy

CEO, Demy-Colton

7mo

Wonderful news, Anna and team.

1 Reaction

Paula Norbom

⚙️Health Technology Talent Advisory Expert (Biotech, Pharmaceutical, Digital Health & Medical Device) 🚀Executive Search | Recruiting | Contract Professionals | 🔗Founder & Moderator Serious Talent®️ Chats

6mo

Just reading this now, Anna. Congratulations on your Notice of Allowance from the Japanese Patent Office!